Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Randomised Period: Placebo	0	15
Total, all-cause mortality	Randomised Period: Spesolimab	0	28
Total, all-cause mortality	Spesolimab Crossover Period	0	27
Total, all-cause mortality	Placebo Crossover Period	0	15
Total, all-cause mortality	Spesolimab Open Label	0	42
Total, other adverse events	Randomised Period: Placebo	11	15
Total, other adverse events	Randomised Period: Spesolimab	12	28
Total, other adverse events	Spesolimab Crossover Period	1	27
Total, other adverse events	Placebo Crossover Period	4	15
Total, other adverse events	Spesolimab Open Label	25	42
Total, serious adverse events	Randomised Period: Placebo	0	15
Total, serious adverse events	Randomised Period: Spesolimab	3	28
Total, serious adverse events	Spesolimab Crossover Period	1	27
Total, serious adverse events	Placebo Crossover Period	0	15
Total, serious adverse events	Spesolimab Open Label	5	42

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05856526/event-totals